^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma: Suggested treatment regimens...CLL/SLL with del(17p)/TP53 mutation…relapsed/refractory therapy…other recommended regimens…lenalidomide ± rituximab
Source:
Title:
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
Excerpt:
......
Trial ID:
Source:
Title:
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
Excerpt:
TP53 mutations were identified in 36 (37.5%) patients, unmutated IGHV in 68 (77.5%) patients and del(17p) in 23 (24.7) patients….Median PFS in patients with TP53 mutations, compared with those without, was short with 11.0 vs 9.5 months (P=0.665; Figure 1a); median OS was 19.4 vs 35.4 months (P=0.249; Table 1)....lenalidomide activity is seen in relapsed and refractory CLL patients with unfavorable cytogenetic profiles, with ORRs of 36.1% and 39.1% observed in patients with TP53 mutations and unmutated IGHV, respectively.
DOI:
10.1038/bcj.2016.9
Source:
Title:
TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)
Excerpt:
A total of 104 patients were enrolled...Del(17p) and TP53 mutation were found in 23/93 (25%) and 36/96 (38%) patients, respectively; 20 patients with TP53 mutation did not have del(17p)….Median PFS in patients with and without TP53 mutation was 47.6 weeks (95% CI 20.6-117.6) vs. 41.1 weeks (95% CI 21.4-85.1) (p = 0.584)...Single-agent lenalidomide treatment led to similar responses, PFS, and OS in rel/ref CLL patients with or without TP53 mutations
DOI:
10.1182/blood.V122.21.1638.1638
